The overall conclusion is that although certain strategies reduce plasma levels of inflammatory mediators, convincing evidence of significant clinical benefits is yet to come.
The objective is to keep this guidance very practical, highlighting the knowledge gaps and areas of uncertainty where randomized clinical trials (RCTs) are desperately needed.